Ascendis Pharma A/S (ASND)
After hours:
| Previous Close | 133.13 |
| Open | 133.62 |
| Bid | 133.40 x 200 |
| Ask | 133.66 x 100 |
| Day's Range | 132.59 - 135.83 |
| 52 Week Range | 83.75 - 161.00 |
| Volume | |
| Avg. Volume | 331,885 |
| Market Cap | 7.556B |
| Beta (5Y Monthly) | 0.53 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -9.53 |
| Earnings Date | May 02, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 0.30 |
GlobeNewswireLatest Clinical and Quality-of-Life Data for TransCon™ PTH (Palopegteriparatide)-Treated Adults with Chronic Hypoparathyroidism to Be Presented at ECE 2024
COPENHAGEN, Denmark, May 09, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that new TransCon PTH (palopegteriparatide) data supporting clinical and quality-of-life benefits in adult patients with chronic hypoparathyroidism will be presented at the European Congress of Endocrinology being held May 11-14, 2024, in Stockholm. Topics include an oral presentation of new 2-year results from a post-hoc analysis of the Phase 3 PaTHway Trial demonstrating sustained improveme
Insider MonkeyAscendis Pharma A/S (NASDAQ:ASND) Q1 2024 Earnings Call Transcript
Ascendis Pharma A/S (NASDAQ:ASND) Q1 2024 Earnings Call Transcript May 4, 2024 Ascendis Pharma A/S isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, and welcome to the Q1 2024 Ascendis Pharma Earnings Conference Call. At this time, all […]
Simply Wall St.Ascendis Pharma First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Ascendis Pharma ( NASDAQ:ASND ) First Quarter 2024 Results Key Financial Results Revenue: €95.9m (up 186% from 1Q...
